Diverse Effects of Oats on Cholesterol Metabolism in C57BL/6 Mice Correlate with Expression of Hepatic Bile Acid-producing Enzymes
Overview
Authors
Affiliations
Purpose: We previously reported that two substrains of C57BL/6 mice respond differently to oats with respect to reduction in plasma cholesterol. Analysis of this difference might offer clues to mechanisms behind the cholesterol-lowering effect of oats. Here, we address the possible roles of hepatic steroid metabolism and the intestinal microbiota in this respect.
Methods: Female C57BL/6 mice were fed an atherogenic diet with oat bran (27 %) or control fibres for 4 weeks.
Results: C57BL/6 NCrl mice responded to oat bran with 19 ± 1 % (P < 0.001) lower plasma cholesterol, 40 ± 5% (P < 0.01) higher excretion of bile acids and increased expression of the bile acid-producing hepatic enzymes CYP7A1 and CYP8B1, but none of these effects were found in C57BL/6JBomTac mice. However, on control diet, C57BL/6JBomTac had tenfold higher expression of CYP7A1 and levels of hepatic cholesterol esters than C57BL/6NCrl mice. Plasma levels of fructosamine indicated improved glycemic control by oat bran in C57BL/6NCrl but not in C57BL/6JBomTac. C57BL/6JBomTac had higher intestinal microbiota diversity, but lower numbers of Enterobacteriaceae, Akkermansia and Bacteroides Fragilis than C57BL/6NCrl mice. Oat bran increased bacterial numbers in both substrains. Microbiota diversity was reduced by oats in C57BL/6JBomTac, but unaffected in C57BL/6NCrl.
Conclusions: Our data do not support a connection between altered microbiota diversity and reduced plasma cholesterol, but the bacterial composition in the intestine may influence the effects of added fibres. The cholesterol-lowering properties of oats involve increased production of bile acids via the classical pathway with up-regulation of CYP7A1 and CYP8B1. Altered cholesterol or bile acid metabolism may interfere with the potential of oats to reduce plasma cholesterol.
Akkermansia muciniphila: biology, microbial ecology, host interactions and therapeutic potential.
Ioannou A, Berkhout M, Geerlings S, Belzer C Nat Rev Microbiol. 2024; 23(3):162-177.
PMID: 39406893 DOI: 10.1038/s41579-024-01106-1.
Aggarwal V, Sunder S, Rastogi Verma S Folia Microbiol (Praha). 2022; 67(6):811-824.
PMID: 35596115 PMC: 9122250. DOI: 10.1007/s12223-022-00973-6.
Xu D, Feng M, Chu Y, Wang S, Shete V, Tuohy K Front Immunol. 2021; 12:787797.
PMID: 34956218 PMC: 8697019. DOI: 10.3389/fimmu.2021.787797.
Dehghanbanadaki H, Aazami H, Keshavarz Azizi Raftar S, Ashrafian F, Ejtahed H, Hashemi E BMC Med Inform Decis Mak. 2020; 20(1):291.
PMID: 33167984 PMC: 7654583. DOI: 10.1186/s12911-020-01312-w.
Koay Y, Chen Y, Wali J, Luk A, Li M, Doma H Cardiovasc Res. 2020; 117(2):435-449.
PMID: 32267921 PMC: 8599768. DOI: 10.1093/cvr/cvaa094.